BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FINOX Biotech Release: CHMP Adopts Positive Opinion For BEMFOLA® For Treatment Of Infertility


1/23/2014 11:26:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Burgdorf, Switzerland, January 23rd 2014 – FINOX Biotech (Finox AG) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorisation Application (MAA) for BEMFOLA® (follitropin alfa solution for injection in pre-filled pens), a biosimilar follicle stimulating hormone used for the treatment of infertility. The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU). If approved, BEMFOLA® could be available in the EU in the second quarter of 2014

To date, nearly 400 patients have received at least one dose of BEMFOLA® in Phase I or III studies. The MAA for BEMFOLA® is supported primarily by data from one Phase III study, in which BEMFOLA® therapy was found to be similar to the currently available treatment with GONAL-f®, based on the numbers of oocytes retrieved after completing FSH therapy. In this Phase III study, similar efficacy and safety profiles were observed between the two study arms and similar numbers of live babies were born to patients who became pregnant following completion of therapy.

Gavin Jelic-Masterton, CEO of FINOX Biotech commented, “We are thrilled that the CHMP has given a positive opinion for BEMFOLA®. This is a great achievement for FINOX Biotech and for our investors. We can now look forward to offering IVF Specialists and patients more choice in their product and delivery system”.

Dr. h.c. Willy Michel, President of the Board of FINOX Biotech added, “Finox Biotech have done extraordinarily well in bringing a recombinant protein to a CHMP positive opinion in the European Union. This demonstrates the commitment of the team to delivering a high quality medicine that will use a Swissengineered state-of–the-art delivery device”.

About BEMFOLA®

BEMFOLA® was produced using recombinant DNA technology. Both BEMFOLA® and the reference product GONAL-f® are formulations of the naturally occurring hormone FSH, which plays a key role in human reproduction. BEMFOLA® is the result of a targeted drug development process aimed to replicate as closely as possible the reference product. The brief to the development engineers when designing the BEMFOLA® injector device was to produce a Pen that absolutely minimised the number of steps a patient needs to take when preparing the injection and to ensure that the patient and physician had maximum control and the least chance of a patient error. The result, the BEMFOLA® Pen, is therefore a simple, single-use, once-a-day disposable device, which allows the patient to self-inject. Accordingly the BEMFOLA® Pen won a ‘Red-Dot’ design award as an indication of just how successfully it fulfils its brief.

About BEMFOLA® in other clinical development programs

FINOX Biotech has agreed with the US-FDA to conduct a pivotal phase III study (FIN3002) for registration of BEMFOLA® (AFOLIA) in the USA. A US-IND has been opened and the FIN3002 study is now in progress.

About FINOX Biotech

FINOX Biotech (FINOX AG) is a biopharmaceutical company with its corporate headquarters in Burgdorf, Switzerland. Finox’ first product will be BEMFOLA®, a biosimilar r-FSH of GONAL-f®. FINOX Biotech was founded in 2007 with a vision to become a leading company in the field of fertility therapies, by combining high quality Swiss medicines with innovative, award-winning delivery devices.

For further information please visit www.finox.ch or contact our CEO, Gavin Jelic-Masterton (gavin.jelic-masterton@finox.ch / +41 79 444 4110) FINOX Biotech / Technikumstrasse 2 / 3401 Burgdorf / Switzerland

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES